AstraZeneca corporate medicines webpage: inaccurate black triangle status breached Clause 26.2

📊

Key facts

⌄

Case number	AUTH/3919/6/24
Company	AstraZeneca UK Limited
Complainant	Anonymous, contactable complainant (clinician)
Material/channel	AstraZeneca UK corporate website medicines webpage (public-facing) with links to SPCs on emc
Time period at issue	May 2023 to November 2023 (as alleged/considered)
Main issue	Inaccurate presentation of black triangle status for Calquence, Fasenra and Lokelma; allegation that Imjudo was missing
Applicable Code year	2021
Breach	Clause 26.2
No breach	Clauses 2, 5.1, 9.1, 26.2 (Imjudo aspect), 26.4
Sanctions	Undertaking received; additional sanctions not stated
Complaint received	5 June 2024
Case completed	30 June 2025
Appeal	No appeal

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

A clinician complained about AstraZeneca’s UK corporate website medicines webpage (a public-facing list of medicines with links to SPCs on emc).
The complainant alleged black triangle errors between May 2023 and November 2023:
- Calquence listed without a black triangle.
- Fasenra and Lokelma listed with a black triangle when not required.
- Imjudo (a black triangle product) missing from the list.
AstraZeneca said the page was non-promotional and intended for the public, with a disclaimer, and each medicine linked directly to the SPC on emc.
AstraZeneca also explained that in November 2023 it removed the static list and replaced it with a link to the live AstraZeneca medicines list on emc to reduce the risk of information becoming out of date.

⚖️

⌄

Breach of Clause 26.2 (in relation to Calquence, Fasenra and Lokelma black triangle status being presented inaccurately).
No breach of Clause 26.2 (in relation to Imjudo being missing from the list).
No breach of Clause 26.4.
No breach of Clause 9.1.
No breach of Clause 5.1.
No breach of Clause 2.

📖

⌄

Clause 26.2 Providing inaccurate information for the public (Breach).
Clause 2 Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry (No breach).
Clause 5.1 Requirement to maintain high standards at all times (No breach).
Clause 9.1 Requirement that all relevant personnel concerned with the preparation or approval of material or activities covered by the Code must be fully conversant with the Code and the relevant laws and regulations (No breach).
Clause 26.2 Requirement that information about prescription only medicines which is made available to the public must be factual, balanced, must not raise unfounded hopes of successful treatment or encourage the public to ask their health professional to prescribe a specific prescription only medicine (No breach).
Clause 26.4 Requirement to include the black triangle in material which relates to a medicine subject to additional monitoring and that is intended for patients taking that medicine (No breach).

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access